J C Javitt1. 1. Center for Sight, Georgetown University Medical Center, Washington, DC, USA.
Abstract
OBJECTIVE: Diabetic retinopathy, which leads to macular oedema and retinal neovascularisation, is the leading cause of blindness among working age Americans. Research has demonstrated significant cost savings associated with detection of eye disease in Americans and Europeans with insulin-dependent diabetes mellitus (IDDM, type I diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, type II diabetes). In this report, we estimate the current and potential savings in both the United States and in a European country resulting from the screening and treatment of retinopathy in persons with diabetes. DESIGN: Computer modelling, incorporating data from population-based epidemiological studies and multicentre clinical trials. Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings. RESULTS: Detection and treatment of diabetic eye disease in both the United States and Scandinavia is not only cost effective, but is actually cost saving from the governmental perspective. Potential savings in the United States exceed $US600 million annually, while, in Sweden, potential savings of 36 million SEK might be realised. These findings are comparable given the differences in population between the 2 countries. CONCLUSIONS: Our analysis indicates that prevention programmes aimed at improving eye care for persons with diabetes not only reduce needless vision loss, but also provide a financial return on the investment of public funds.
OBJECTIVE:Diabetic retinopathy, which leads to macular oedema and retinal neovascularisation, is the leading cause of blindness among working age Americans. Research has demonstrated significant cost savings associated with detection of eye disease in Americans and Europeans with insulin-dependent diabetes mellitus (IDDM, type I diabetes) and non-insulin-dependent diabetes mellitus (NIDDM, type II diabetes). In this report, we estimate the current and potential savings in both the United States and in a European country resulting from the screening and treatment of retinopathy in persons with diabetes. DESIGN: Computer modelling, incorporating data from population-based epidemiological studies and multicentre clinical trials. Monte Carlo simulation was used, combined with sensitivity analysis and present value analysis of cost savings. RESULTS: Detection and treatment of diabetic eye disease in both the United States and Scandinavia is not only cost effective, but is actually cost saving from the governmental perspective. Potential savings in the United States exceed $US600 million annually, while, in Sweden, potential savings of 36 million SEK might be realised. These findings are comparable given the differences in population between the 2 countries. CONCLUSIONS: Our analysis indicates that prevention programmes aimed at improving eye care for persons with diabetes not only reduce needless vision loss, but also provide a financial return on the investment of public funds.
Authors: B E Klein; M D Davis; P Segal; J A Long; W A Harris; G A Haug; Y L Magli; S Syrjala Journal: Ophthalmology Date: 1984-01 Impact factor: 12.079
Authors: David B Rein; John S Wittenborn; Xinzhi Zhang; Benjamin A Allaire; Michael S Song; Ronald Klein; Jinan B Saaddine Journal: Health Serv Res Date: 2011-04-14 Impact factor: 3.402
Authors: Michal Laron; Marcus A Bearse; Kevin Bronson-Castain; Soffia Jonasdottir; Barbara King-Hooper; Shirin Barez; Marilyn E Schneck; Anthony J Adams Journal: Invest Ophthalmol Vis Sci Date: 2012-01-25 Impact factor: 4.799
Authors: David B Rein; John S Wittenborn; Xinzhi Zhang; Thomas J Hoerger; Ping Zhang; Barbara Eden Kobrin Klein; Kris E Lee; Ronald Klein; Jinan B Saaddine Journal: Arch Ophthalmol Date: 2012-05
Authors: Gwénolé Quellec; Mathieu Lamard; Pierre Marie Josselin; Guy Cazuguel; Béatrice Cochener; Christian Roux Journal: IEEE Trans Med Imaging Date: 2008-09 Impact factor: 10.048